CRSP:NSD-CRISPR Therapeutics AG (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 53.02

Change

+0.80 (+1.53)%

Market Cap

USD 0.79B

Volume

4.77M

Analyst Target

USD 95.21
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CRISPR Therapeutics AG is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.57 (+1.82%)

USD 118.90B
ARGX argenx NV ADR

+7.35 (+1.15%)

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

+0.49 (+0.20%)

USD 34.99B
ONC BeiGene, Ltd.

+7.51 (+3.17%)

USD 25.62B
RPRX Royalty Pharma Plc

+0.74 (+2.27%)

USD 18.65B
SMMT Summit Therapeutics PLC

+1.46 (+6.76%)

USD 17.52B
UTHR United Therapeutics Corporatio..

-13.42 (-3.52%)

USD 15.68B
INCY Incyte Corporation

+1.22 (+1.74%)

USD 14.29B
INSM Insmed Inc

-0.22 (-0.26%)

USD 13.70B
MRNA Moderna Inc

-2.17 (-6.04%)

USD 12.93B

ETFs Containing CRSP

XDNA 15.28 % 0.00 %

N/A

N/A
ARCG:LSE ARK Genomic Revolution UC.. 6.32 % 0.00 %

-28.50 (-4.98%)

USD 5.84M
ARKG:LSE ARK Genomic Revolution UC.. 6.32 % 0.00 %

-0.33 (-4.98%)

USD 5.84M
GNOG:LSE Global X Genomics & Biote.. 4.02 % 0.00 %

-0.08 (-4.98%)

USD 9.83M
NXTE Investment Managers Serie.. 4.01 % 0.00 %

-0.36 (-4.98%)

N/A
ARCK:LSE ARK Innovation UCITS ETF .. 3.97 % 0.00 %

-29.70 (-4.98%)

USD 0.04B
ARKK:LSE ARK Innovation UCITS ETF .. 3.97 % 0.00 %

-0.34 (-4.98%)

USD 0.04B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

-1.25 (-4.98%)

USD 1.32B
ARKK ARK Innovation ETF 0.00 % 0.75 %

-1.73 (-4.98%)

USD 7.17B
AIIQ 0.00 % 0.79 %

N/A

N/A
ERSX 0.00 % 0.00 %

N/A

N/A
LS:CA 0.00 % 2.21 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.13 (-4.98%)

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 34.71% 89% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.71% 89% A- 92% A
Trailing 12 Months  
Capital Gain -35.66% 49% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.66% 49% F 24% F
Trailing 5 Years  
Capital Gain -0.02% 74% C 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.02% 74% C 44% F
Average Annual (5 Year Horizon)  
Capital Gain 0.29% 51% F 40% F
Dividend Return 0.29% 50% F 35% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.92% 60% D- 35% F
Risk Adjusted Return 0.52% 51% F 35% F
Market Capitalization 0.79B 94% A 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.53 37% 62%
Price/Book Ratio 1.91 56% 51%
Price / Cash Flow Ratio -14.50 85% 86%
Price/Free Cash Flow Ratio 14.16 5% 27%
Management Effectiveness  
Return on Equity -13.07% 92% 47%
Return on Invested Capital -12.00% 80% 39%
Return on Assets -9.57% 89% 35%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.